Spectral CT in Radiotherapy for Cervical Cancer

May 27, 2024 updated by: Peking Union Medical College Hospital

The Clinical Research of Spectral CT in Radiotherapy for Cervical Cancer

The purpose of this study was to explore the potential application of spectral CT for radiotherapy in cervical cancer.

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Study Type

Observational

Enrollment (Estimated)

150

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

  • China
    • Beijing
      • Beijing, Beijing, China, 100010
        • Recruiting
        • Peking Union Medical College Hospital
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

adult patients with newly stablished diagnosis of cervical cancer complying with selection criteria for cervical cancer.

Description

Inclusion Criteria:

  1. All patients were confirmed cervical cancer by pathology
  2. patients were treated with concurrent chemoradiotherapy
  3. Spectral CT scans acquisition performed during the arterial phase and venous phase
  4. All the patients underwent a 18F-FDG PET/CT before treatment

Exclusion Criteria:

  1. CT without spectral scans
  2. History of allergy to intravenous contrast
  3. Pregnant or potentially pregnant female subjects

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Comparison of spectral CT derived data with response evaluation in cervical cancer
Time Frame: through study completion, an average of 2 year
To evaluate the tumor response of using quantitative parameters in spectral CT for cervical cancer patients according to RECIST 1.1
through study completion, an average of 2 year

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Identifying metastatic lymph nodes in cervical cancer with spectral CT
Time Frame: through study completion, an average of 2 year
To evaluate the diagnostic performances of using spectral CT for identifying metastatic lymph nodes in patients with cervical cancer
through study completion, an average of 2 year
Application of energy spectrum CT in brachytherapy of cervical cancer
Time Frame: through study completion, an average of 2 year
The ability to reduce metal artifact and assist in target delineation
through study completion, an average of 2 year

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Peking Union Medical College Hospital

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

May 22, 2024

Primary Completion (Estimated)

May 22, 2026

Study Completion (Estimated)

December 31, 2026

Study Registration Dates

First Submitted

May 8, 2024

First Submitted That Met QC Criteria

May 27, 2024

First Posted (Actual)

May 30, 2024

Study Record Updates

Last Update Posted (Actual)

May 30, 2024

Last Update Submitted That Met QC Criteria

May 27, 2024

Last Verified

May 1, 2024

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • SPRTCC-Trial

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

Yes

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Cervical Cancer

Clinical Trials on Spectral computed tomography scan

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Algeria

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe